Digital Therapeutics Strategic, Scientific, Developmental, and Regulatory Aspects |
|
| Editor:
| Sverdlov, Oleksandr
van Dam, Joris |
| Series title: | Chapman and Hall/CRC Biostatistics Ser. |
| ISBN: | 978-1-003-01728-8 |
| Publication Date: | Dec 2022 |
| Publisher: | CRC Press LLC
|
| Imprint: | Chapman & Hall/CRC |
| Book Format: | Digital (delivered electronically) |
| List Price: | USD $220.00USD $330.00USD $245.00 |
Book Description:
|
One of the hallmarks of the 21st century medicine is the emergence of digital therapeutics (DTx)--evidence-based, clinically validated digital technologies to prevent, diagnose, treat, and manage various diseases and medical conditions. DTx solutions have been gaining interest from patients, investors, healthcare providers, health authorities, and other stakeholders because of the potential of DTx to deliver equitable, massively scalable, personalized and transformative treatments...
More Description
One of the hallmarks of the 21st century medicine is the emergence of digital therapeutics (DTx)--evidence-based, clinically validated digital technologies to prevent, diagnose, treat, and manage various diseases and medical conditions. DTx solutions have been gaining interest from patients, investors, healthcare providers, health authorities, and other stakeholders because of the potential of DTx to deliver equitable, massively scalable, personalized and transformative treatments for different unmet medical needs.
Digital Therapeutics: Scientific, Statistical, Clinical, and Regulatory Aspects is an unparalleled summary of the current scientific, statistical, developmental, and regulatory aspects of DTx which is poised to become the fastest growing area of the biopharmaceutical and digital medicine product development. This edited volume intends to provide a systematic exposition to digital therapeutics through 19 peer-reviewed chapters written by subject matter experts in this emerging field.
This edited volume is an invaluable resource for business leaders and researchers working in public health, healthcare, digital health, information technology, and biopharmaceutical industries. It will be also useful for regulatory scientists involved in the review of DTx products, and for faculty and students involved in an interdisciplinary research on digital health and digital medicine.